Haemonetics Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HAZ.F | 0YX.F | XVIVO.ST | ITGR | TMDX | GTN0.F | |
|---|---|---|---|---|---|---|
| Market cap | 5.05B | 6.53B | 6.37B | 4.31B | 2.52B | 7.01B |
| P/E (TTM) | 62.7 | 31.0 | 49.4 | 42.5 | 18.8 | 26.3 |
| Forward P/E | 37.0 | — | 34.2 | 18.4 | 32.3 | — |
| Price/book | 6.8 | 2.4 | 2.8 | 2.5 | 4.9 | 0.2 |
| Dividend yield | — | 2.16% | — | — | — | 1.80% |
| 1-year change | +146.51% | +19.77% | +10.74% | +85.72% | −45.89% | +22.84% |
| Today | +4.72% | +2.89% | +0.60% | +0.07% | +8.04% | +3.31% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All HAZ.F news ›Analysts’ Top Healthcare Picks: Haemonetics (HAE), Climb Bio (CLYM)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Haemonetics (HAE), Climb Bio (CLYM) and Compass Therapeutics (CMPX) with bullish sentiments. In a report released today, Michael Petusky from…
Haemonetics Shows Rising Relative Strength; Still Shy Of Key Threshold
A Relative Strength Rating upgrade for Haemonetics shows improving technical performance. Will it continue? Investors.com will undergo scheduled maintenance from 6:00 PM ET to 9:00 PM ET and some features may be unavailable. We apologize…
Haemonetics Hits 80-Plus Relative Strength Rating Benchmark
Haemonetics sees its Relative Strength Rating enter the 80-plus level. Investors.com will undergo scheduled maintenance from 6:00 PM ET to 9:00 PM ET and some features may be unavailable. We apologize for any inconvenience. One important…
Recon: AZ, Oracle partner for AI-powered clinical trials; FDA approves Haemonetics vascular closure system
The complete guide to formulating an effective global regulatory strategy for medical devices, created and curated by experts. Where regulatory professionals collaborate and make connections that last a lifetime. Regulatory Recon is our…
FDA Clears Haemonetics PerQseal Elite Vascular Closure System
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. FDA Clears Haemonetics PerQseal Elite Vascular Closure System Zero…
More from 4 other outlets
- Vascular News Haemonetics announces US FDA approval of PerQseal Elite vascular closure system
- wincountry.com Haemonetics says FDA clears vascular closure device
- Seeking Alpha Haemonetics wins approval of PerQseal Elite vascular closure system
- @PRNewswire Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
Haemonetics Gets FDA Approval for Vascular Closure Device
Published on 10/19/2026 at 05:09 pm EDT - Modified on 10/19/2026 at 05:11 pm EDT Haemonetics received approval from U.S. regulators for its PerQseal Elite vascular closure system for use in large-bore arterial procedures. The medical…
Haemonetics Says CSL Plasma to Complete Rollout of Products by End-2027
Haemonetics said in a filing Thursday that CSL Plasma expects to complete the rollout of Haemonetics' devices and disposables by the end of 2027. CSL expects all of its US plasma collection... Medical Equipment, Supplies & Distribution…
CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform
CSL said it will transition its US plasma collection centers to Haemonetics' latest-generation plasmapheresis platform, with the rollout expected to be completed by the end of 2027, according to... CSL to Transition US Plasma Centers to…
Morning Movers: Haemonetics up sharply after CSL Plasma supply pact
The broader setup is increasingly a tug-of-war between strong expected earnings and deteriorating macro conditions. LSEG expects S&P 500 earnings to rise 30.6% in the third quarter, but the market is confronting a 10-year yield near 5.35%,…
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Haemonetics Corporation’s HAE impressive MedSurg business is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth. However, fierce competitive pressure and…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com9
- investors.com2
- markets.businessinsider.com2
- stockstotrade.com2
- timothysykes.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 31 articles, not a forecast.